Tas-102

Esophageal Cancer

Taiho Pharmaceutical Co., Ltd.unclassifiedPhase 1Active

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

130 Active assets in the Esophageal Cancer cohort.

Asset / Sponsor	Phase	Rating
Tisotumab Vedotin Seagen Inc.	Phase 2	BB
FLUOROURACILUM Merck Sharp & Dohme LLC	Phase 4	BB
Benadryl Ciusss de L'Est de l'Île de Montréal	Phase 3	B
Cyclophosphamide Sutro Biopharma, Inc.	Phase 3	B
Epirubicin Sutro Biopharma, Inc.	Phase 3	B

View all 50 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant

BB

Indicative ·

68 / 100

Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant

BB

Indicative ·

68 / 100

Carcinoma, Islet CellDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.